All News ISR Immune System Regulation Holding AB (publ)

Equities

ISR

SE0008212195

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine	23-08-28	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
ISR Receives Approval To Conduct Clinical Trial In Bangladesh	22-07-01	MT
SARS-CoV-2 vaccine study approved by Bangladesh BMRC	22-07-01	AQ
ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc	22-07-01	CI
ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.	22-06-28	AQ
ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III	22-06-28	CI
Delegation from Bangladesh visits ISR for study preparation	22-06-20	AQ
ISR Immune System Regulation : Holding Annual Report and Consolidated Accounts 2021 (eng) (PDF)	22-06-14	PU
Redeye Initiates Coverage of ISR Holding	22-05-05	AQ
ISR - Immune System Regulation Holding AB (publ.) 2[nd] half of 2021, including year-end report is now published on the website: www.israb.se	22-02-23	PU
ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Iconovo : ISR to Test Inhalable, Nasal COVID-19 Vaccines in Bangladesh	21-08-27	MT
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Iconovo : receives an order for additional work from ISR for development of a nasal COVID-19 vaccine	21-07-12	AQ
BioStock: Iconovo and ISR develop new covid-19 inhalation vaccine	21-04-01	AQ
Iconovo : signs agreement with ISR for the development of inhaled covid-19 vaccine	21-03-31	AQ
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News ISR Immune System Regulation Holding AB (publ)

Equities

ISR

SE0008212195

All News

Filters